Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Roche (OTCQX: RHHBY) reported positive Phase II topline results for CT-388, a once-weekly dual GLP-1/GIP agonist for obesity. At the highest tested dose (24 mg) CT-388 achieved a placebo-adjusted weight loss of 22.5% (efficacy estimand) and 18.3% (treatment-regimen estimand) at 48 weeks, with a clear dose-response and no weight-loss plateau. At 24 mg, 95.7% lost ≥5%, 87% lost ≥10%, 47.8% lost ≥20%, and 26.1% lost ≥30% at week 48. 73% of pre-diabetic participants normalized blood glucose versus 7.5% for placebo. Safety was consistent with the incretin class; discontinuations for AEs were 6%. Phase III programme (Enith1/Enith2) is expected to start this quarter.
Genentech (OTCQX: RHHBY) will more than double its initial investment in a new Holly Springs, North Carolina biomanufacturing facility to approximately $2 billion, expanding the project announced in May 2025 and begun in August 2025. The expanded buildout will increase production capacity for next-generation metabolic treatments, leverage advanced biomanufacturing, automation, and digital tools, and aim to be operational by 2029. The project is expected to support more than 2,000 jobs (including 500+ high-wage manufacturing roles and 1,500+ construction jobs) and reinforces Roche and Genentech’s broader $50 billion U.S. manufacturing and R&D commitment.
Roche (RHHBY) announced FDA approval of Lunsumio VELO (mosunetuzumab) subcutaneous for adult patients with relapsed or refractory follicular lymphoma after two or more prior therapies, granted under accelerated approval on 22 December 2025.
Approval is based on the GO29781 trial where Lunsumio VELO showed an objective response rate 75% and complete response rate 59% in third-line or later FL, with a median duration of response of 22.4 months. The SC formulation reduces administration time to ~one minute versus 2–4 hour IV infusions and can be given as a fixed-duration regimen as short as six months. The most common adverse reactions included injection site reactions, fatigue, rash and cytokine release syndrome (CRS, 30%; Grade 3: 2.1%).
Genentech (OTCQX: RHHBY) announced FDA accelerated approval of Lunsumio VELO (mosunetuzumab-axgb) as a subcutaneous treatment for adult patients with relapsed or refractory follicular lymphoma after two or more prior systemic therapies, based on the Phase I/II GO29781 study.
Key trial results: ORR 75%, CR 59%, median duration of response 22.4 months. Administration is a ~one-minute subcutaneous injection versus a 2–4 hour IV infusion; treatment can be fixed-duration (as short as six months). Approval is accelerated and may require confirmatory trial verification. Common adverse reactions include injection site reactions, fatigue, rash and cytokine release syndrome (CRS) occurred in 30% (mostly Grade 1–2).
Genentech (OTCQX: RHHBY) announced an agreement with the U.S. government on December 19, 2025 that aims to lower prescription drug costs for state Medicaid programs, expand direct-to-patient access for its influenza medicines via TrumpRx.gov, and encourage other wealthy countries to reward biopharmaceutical innovation.
The company reaffirmed a $50 billion U.S. investment in manufacturing, infrastructure, and R&D, cited support for more than 11,000 jobs (including ~6,500 construction jobs) and up to 1,000 new skilled roles, and secured a three-year tariff exemption to enable continued onshoring. Specific agreement terms remain confidential.
Roche (OTCQX: RHHBY) announced U.S. launch of cobas 6800/8800 systems version 2.0 and software v2.0.1 after FDA 510(k) clearance earlier in 2025. The upgrade increases assay flexibility (unique assays per run 3→6), allows up to 6 assays per sample, and supports simultaneous LDT and IVD testing. A second analytic unit option for cobas 6800 can boost throughput to 2,112 tests/day. The update is available as a software upgrade to existing systems and aims to reduce downtime, consolidate test menus, and address staffing and cost pressures while modernizing the user interface.
Roche (OTCQX: RHHBY) announced on 11 December 2025 that it secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring, expanding its automated cobas Mass Spec IVD menu to 39 tests. The menu already covers therapeutic drug monitoring for immunosuppressants and antibiotics, steroid hormones and vitamin D metabolites, and aims to bring gold-standard mass spectrometry into routine labs via a fully automated workflow that reduces turnaround times and standardises results. Roche also reported a CLIA “moderate complexity” designation in the US for the first analyte, and said the solution is available in selected CE-mark markets and other countries including the UK, Canada and Japan. Roche plans further menu expansion and ongoing regulatory engagement.
Genentech (OTCQX: RHHBY) announced positive Phase III lidERA results showing adjuvant giredestrant reduced the risk of invasive disease recurrence or death by 30% (HR=0.70, 95% CI 0.57-0.87, p=0.0014) versus standard-of-care endocrine therapy in ER-positive, HER2-negative early-stage breast cancer.
At three years, iDFS was 92.4% with giredestrant vs 89.6% with SoC ET; distant recurrence-free interval improved by 31% (HR=0.69). Overall survival data were immature at interim analysis. Data to be presented at the 2025 San Antonio Breast Cancer Symposium.
Roche (OTCQX: RHHBY) announced positive phase III lidERA results showing investigational oral SERD giredestrant reduced the risk of invasive disease recurrence or death by 30% versus standard-of-care endocrine therapy (HR=0.70, 95% CI 0.57-0.87, p=0.0014) in ER-positive, HER2-negative early-stage breast cancer (pre-specified interim analysis).
At three years, 92.4% of patients on giredestrant were alive and free of invasive disease versus 89.6% with SoC ET. Giredestrant also cut distant recurrence risk by 31% (HR=0.69). Overall survival data are immature; safety was described as manageable. Results will be presented at the 2025 San Antonio Breast Cancer Symposium.
Roche (OTCQX: RHHBY) received the CE Mark for its cobas® BV/CV PCR assay on 9 December 2025 to detect bacteria causing bacterial vaginosis and yeast causing candida vaginitis from a single vaginal swab.
The test enables broader sexual health testing on cobas 5800/6800/8800 systems without an additional sample, aims to improve diagnostic accuracy versus microscopy/pH/clinical observation, and is now available in countries accepting the CE Mark.
Market context: the global sexual health segment is valued at CHF 1.1 bn with 11% annual growth; vaginitis growth is cited at 26% yearly.